VAW vs XBI
Vanguard Materials ETF vs SPDR S&P Biotech ETF
- • VAW has the lower expense ratio at 0.09% vs 0.35% for XBI.
- • VAW pays a higher dividend yield (1.37%).
Side-by-side metrics
| Metric | VAW | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.09% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.37% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $4.54B | $8.30B |
YTD return | 14.25% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.02 | 1.09 |
P/E ratio | 25.98 | — |
Last price | $232.03 | $133.66 |
Inception | — | — |
Issuer | Vanguard | State Street |
VAW top holdings
| LIN | Linde PLC | 15.14% |
| NEM | Newmont Corp | 7.73% |
| FCX | Freeport-McMoRan Inc | 5.52% |
| SHW | Sherwin-Williams Co | 4.94% |
| CRH | CRH PLC | 4.61% |
| ECL | Ecolab Inc | 4.44% |
| APD | Air Products and Chemicals Inc | 4.05% |
| CTVA | Corteva Inc | 3.70% |
| NUE | Nucor Corp | 2.53% |
| VMC | Vulcan Materials Co | 2.35% |
XBI top holdings
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
About VAW
VAW (Vanguard Materials ETF) is US materials sector stocks. Managed by Vanguard, the fund carries $4.5B in assets under management, an expense ratio of 0.09%, a dividend yield of 1.37%. Its largest holding is Linde PLC (LIN), which represents 15.1% of the portfolio. Consumer Cyclical is the fund's largest sector exposure at 9.2%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.